Navigation Links
Wisconsin cannot afford to take a pass on Doyles biotech plan

nduct world-class work, theyll need agreements to use those lines. There are only a few states that can hope to compete with the go-go Californians, and Wisconsin is among them.

Wisconsin cannot compete, however, if state lawmakers fail to see the value of the investment, if stem cell opponents are allowed to block ethically conducted research, and if the another tiresome Madison versus M......

Full article >>>
'"/>

Source:wistechnology.com By Tom Still 12/20/04


Page: 1 2 3

Related biology technology :

1. To be a player in the "Knowledge Economy," Wisconsin needs more tech workers
2. Federal bioenergy lab will give Wisconsin a chance to shine
3. Breaking down Wisconsins angel capital numbers
4. Innovation featured in NE Wisconsin Roundtable
5. Visions: Broderick says Wisconsin should be in top third in venture capital
6. Wisconsin building toward the major leagues of venture capital
7. Wisconsin Supreme Court to hear Menasha software case
8. Wisconsin applicants urged to pursue DOE funding for cellulosic biomass
9. Legislature should look to Wisconsins natural energy advantages
10. Stem cells get most attention, but they are only part of Wisconsins bio-portfolio
11. BIO 2007: Wisconsin makes its presence felt

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Wisconsin cannot afford take pass Doyles biotech plan

(Date:11/6/2009)...Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech..."Company") today announced updated results from a ...nts with sarcomas metastatic to the lung in a post...ue Oncology Society Meeting held in Miami Beach, F...ntation, entitled "A Phase II Study of Intravenous...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 P...h is set to take place on February 22-24, 2010 in ...y conference we will highlight key issues in formi...are their experiences. , ...enda for Arrowhead’s 2010 Personalized Medi...
(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...
(Date:11/5/2009)...Y, N.J., Nov. 5 DSM Pharmaceutical...acturing alliance with Galenix, Saint Jean D,Illac...al scale manufacturing partner for Galenix commerc...nix will collaborate on business development oppor...logies, based on the strength of Galenix in drug p...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...UT CREEK, CAGenomics is accelerating improvements ...ernative to fossil fuel for the nation,s transport....S. Department of Energy Joint Genome Institute (D...Nature . In "Genomics of cellulosic biofuels," Ru...ic technologies will contribute to a substantially...
...SON Electronic devices get smaller and more compl...price for miniaturization, especially when it come...he floor. Wouldn,t it be great if they bounced ins... University researchers, led by Apparao Rao, profe...f tiny, shock-absorbing carbon springs which possi...
...ON, Mass., Aug. 13 Indevus,Pharmaceuticals, Inc. ....S.,Patent No. 7,410,978 (the ",978 patent"), enti...is licensed exclusively to the Company by the pate...e ,978 patent covers the Company,s approved produc...spium chloride which is indicated for the,treatmen...
Other Biology Technology:DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 2DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 3DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 4Clemson scientists put a (nano) spring in their step 2Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 2Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 3
(Date:11/4/2009)...4 GenVault Corporation (Carlsbad, ...., has joined its Board of Directors. Dr. Brody, ...stitute, is an acclaimed physician-scientist and u...tute, Dr. Brody served as president of The Johns H... Academy of Engineering and the Institute of Medic...
(Date:11/3/2009)...ultimate loner of the ocean, cruising thousands of...rs has discovered that the sharks have maintained ...ens of thousands of years the white sharks in the ...es into a population genetically distinct from sha...a large, highly mobile species," said Salvador Jor...
(Date:11/3/2009)...Ind. - Chief executives in 35 of the top Fortune 5...r "ideal salaries" in 2008, according to a new typ...versity researcher to determine fair CEO compensat...rporate governance issues of the day is how to det...nkatasubramanian, a professor of chemical engineer...
Breaking Biology News(10 mins):Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4New theory on fairness in economics targets CEO pay 2New theory on fairness in economics targets CEO pay 3New theory on fairness in economics targets CEO pay 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 1Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 7NeurogesX Reports Second Quarter 2009 Results 13446 1NeurogesX Reports Second Quarter 2009 Results 13446 2NeurogesX Reports Second Quarter 2009 Results 13446 3NeurogesX Reports Second Quarter 2009 Results 13446 4NeurogesX Reports Second Quarter 2009 Results 13446 5NeurogesX Reports Second Quarter 2009 Results 13446 6NeurogesX Reports Second Quarter 2009 Results 13446 7NeurogesX Reports Second Quarter 2009 Results 13446 8NeurogesX Reports Second Quarter 2009 Results 13446 9NeurogesX Reports Second Quarter 2009 Results 13446 10NeurogesX Reports Second Quarter 2009 Results 13446 11NeurogesX Reports Second Quarter 2009 Results 13446 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 1Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 2Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 3Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 4Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 5Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 6Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 8Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 9Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 10Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 11Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 13Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 14Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 15Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 16Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 17Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 18
... Cancer Research at the University of California, ...rkable property of the contractile ring, a structu...the contractile ring works to divide the cell may ...ontrolled cell division in cancer. , The researc...he length of the contractile ring are reduced duri...
...iety (ACerS) announced today that it is launching ...edicated to glass research: The International Jou...enerations of glass and glass-related materials ar... many of the world,s emerging technologies, includ... environmental, optical and defense technologies s...
.... , In the context of the climatic change of th... global warming are of great interest. That is the...pension of solid or liquid particles on a gaseous ...cooling of the atmosphere. , Juan Luis Guerrero ...nique for atmospheric characterization by elastic ...
Other Biology News:Study may aid efforts to prevent uncontrolled cell division in cancer 2New journal on advanced glass research to debut 2A research work will be the reference to characterize the climatic impact of desert dust 2
GIBCO Streptomycin Sulfate from Invitrogen
GIBCO Dulbeccos Modified Eagle Medium (D-MEM) (1X); powder (low glucose) from Invitrogen
Goat Anti-Adducin beta (C-16) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Rat TNF-alpha ELISA Kit, OptEIA from BD Biosciences Pharmingen
Biology Products: